PIPELINE

Obesity & liver diseases

Product Name

Preclinical

Phase 1

Phase 2

Phase 3

Status¹

Preclinical

Phase 1

Phase 2

Phase 3

Pemvidutide
(ALT-801)

Obesity

55%

Status²

Interim data on 50% of subjects Q1 2023

Pemvidutide
(ALT-801)

NASH

45%

Status²

12-week Phase 1b NAFLD trial data announced Sep 2022

24-week Phase 1b (12-wk extension) trial readout Q4 2022

Preclinical

Phase 1

Phase 2

Phase 3

HepTcell^™

Chronic HBV

55%

Status²

Phase 2 trial readout H2 2023

¹ Expected Dates